AU2016231328B2 - Compounds for improving the half-life of von Willebrand factor - Google Patents

Compounds for improving the half-life of von Willebrand factor Download PDF

Info

Publication number
AU2016231328B2
AU2016231328B2 AU2016231328A AU2016231328A AU2016231328B2 AU 2016231328 B2 AU2016231328 B2 AU 2016231328B2 AU 2016231328 A AU2016231328 A AU 2016231328A AU 2016231328 A AU2016231328 A AU 2016231328A AU 2016231328 B2 AU2016231328 B2 AU 2016231328B2
Authority
AU
Australia
Prior art keywords
leu
gly
gln
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016231328A
Other languages
English (en)
Other versions
AU2016231328A1 (en
Inventor
Gerhard Dickneite
Uwe Kalina
Michael Moses
Sabine Pestel
Stefan Schulte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring Lengnau AG
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Publication of AU2016231328A1 publication Critical patent/AU2016231328A1/en
Application granted granted Critical
Publication of AU2016231328B2 publication Critical patent/AU2016231328B2/en
Assigned to CSL Behring Lengnau AG reassignment CSL Behring Lengnau AG Alteration of Name(s) of Applicant(s) under S113 Assignors: CSL BEHRING RECOMBINANT FACILITY AG
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016231328A 2015-03-06 2016-03-04 Compounds for improving the half-life of von Willebrand factor Ceased AU2016231328B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15158088 2015-03-06
EP15158088.3 2015-03-06
PCT/EP2016/054650 WO2016142289A1 (en) 2015-03-06 2016-03-04 Compounds for improving the half-life of von willebrand factor

Publications (2)

Publication Number Publication Date
AU2016231328A1 AU2016231328A1 (en) 2017-10-26
AU2016231328B2 true AU2016231328B2 (en) 2018-07-05

Family

ID=52629453

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016231328A Ceased AU2016231328B2 (en) 2015-03-06 2016-03-04 Compounds for improving the half-life of von Willebrand factor

Country Status (12)

Country Link
US (1) US20180043012A1 (enExample)
EP (1) EP3265489B1 (enExample)
JP (1) JP6704420B2 (enExample)
KR (1) KR20170125942A (enExample)
CN (1) CN107428831A (enExample)
AU (1) AU2016231328B2 (enExample)
BR (1) BR112017017852A2 (enExample)
CA (1) CA2978134A1 (enExample)
DK (1) DK3265489T3 (enExample)
ES (1) ES2755449T3 (enExample)
SG (1) SG11201706657PA (enExample)
WO (1) WO2016142289A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4217402A1 (en) * 2020-09-23 2023-08-02 Ablevia biotech GmbH Compound for the prevention or treatment of autoantibody-mediated conditions
EP4251272A4 (en) * 2020-11-24 2024-10-09 Band Therapeutics, LLC COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLEEDING DISORDERS
CN116723863A (zh) * 2020-11-24 2023-09-08 邦德治疗有限公司 用于治疗出血性病症的组合物和方法
CN121991252B (zh) * 2026-04-09 2026-07-17 重庆臻伽亦生物科技有限公司 一种基于优化肽接头的多价cd301融合蛋白、功能化磁珠及其在ctc捕获中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167303A1 (en) * 2012-05-08 2013-11-14 Csl Behring Gmbh Sugar compositions for treating hemophilia a and/or von willebrand disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PT1754718E (pt) * 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
CA2465004A1 (en) * 2003-05-19 2004-11-19 National Institute For Biological Standards And Control Composition
JP2005132796A (ja) * 2003-10-31 2005-05-26 Tatsuro Irimura 肉芽組織形成性疾患の治療のための医薬組成物および方法
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
EP2669679A1 (en) * 2012-05-28 2013-12-04 Universitätsklinikum Hamburg-Eppendorf Method for the detection of glycans using polypeptides comprising the CD301 carbohydrate recognition domain
ES2770501T3 (es) * 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
KR20230007555A (ko) * 2013-06-28 2023-01-12 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167303A1 (en) * 2012-05-08 2013-11-14 Csl Behring Gmbh Sugar compositions for treating hemophilia a and/or von willebrand disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Y. SANO ET AL, "Properties of Blocking and Non-blocking Monoclonal Antibodies Specific for Human Macrophage Galactose-type C-type Lectin (MGL/ClecSF10A/CD301)", JOURNAL OF BIOCHEMISTRY, (2006-12-13), vol. 141, no. 1, pages 127 - 136 *

Also Published As

Publication number Publication date
EP3265489A1 (en) 2018-01-10
WO2016142289A1 (en) 2016-09-15
JP2018510213A (ja) 2018-04-12
CN107428831A (zh) 2017-12-01
KR20170125942A (ko) 2017-11-15
ES2755449T3 (es) 2020-04-22
US20180043012A1 (en) 2018-02-15
JP6704420B2 (ja) 2020-06-03
SG11201706657PA (en) 2017-09-28
CA2978134A1 (en) 2016-09-15
DK3265489T3 (da) 2019-07-15
BR112017017852A2 (pt) 2018-04-10
EP3265489B1 (en) 2019-05-08
AU2016231328A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
Stennicke et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
JP7273487B2 (ja) 第ｖｉｉｉ因子キメラおよびハイブリッドポリペプチドならびにその使用法
AU2016231327B2 (en) Modified von Willebrand factor having improved half-life
EP3793588B1 (en) Methods of treating hemophilia a
EP2616486B1 (en) Factor viii variants having a decreased cellular uptake
WO2016070050A1 (en) ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
EP3265489B1 (en) Compounds for improving the half-life of von willebrand factor
WO2016065301A1 (en) Anti-gpiib/iiia antibodies and uses thereof
US20190263890A1 (en) Truncated von willebrand factor polypeptides for treating hemophilia
JP6211598B2 (ja) 血友病ａ及び／又はヴォン・ヴィレブランド病を処置するための糖組成物
HK1245301B (en) Compounds for improving the half-life of von willebrand factor
HK1245301A1 (en) Compounds for improving the half-life of von willebrand factor
KR20180095083A (ko) 응고제로서 사용하기 위한 당단백질 v 억제제
HK1244292B (en) Modified von willebrand factor having improved half-life
FVIII A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
HK40091851A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
HK40011493A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
HK40011493B (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
HK40008359A (en) Truncated von willebrand factor polypeptides for treating hemophilia
HK40008359B (en) Truncated von willebrand factor polypeptides for treating hemophilia
HK1197805A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
HK1197805B (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CSL BEHRING LENGNAU AG

Free format text: FORMER NAME(S): CSL BEHRING RECOMBINANT FACILITY AG

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired